Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea News Release 20170830 Opdivo® (Nivolum Thursday August 31st, 2017By Tokio X'press Pharmaceutical ONO
Gazprom’s profit plunges 80 pct in Q2 Gazprom’s Thursday August 31st, 2017By Tokio X'press LNG, RUS Gazprom
What Flood Insurance Does and Does Not Cover What Flood Insur Thursday August 31st, 2017By Tokio X'press Insurance, USA Consumer Reports
SUMITOMO CORPORATION OF AMERICAS BACKS VERITREAD; Investment in IOT Application for use by Construction Equipment Industry SUMITOMO CORPORA Thursday August 31st, 2017By Tokio X'press JPN SUMITOMO CORPORATION
Sumitomo Chemical Licenses PO Production Technology for Petrochemical Project of Thailand’s Largest Petrochemical and Refining Company News Releases / by SUMITOMO CHEMICAL Sumitomo Chemical Licenses PO Thursday August 31st, 2017By Tokio X'press Chemical, JPN Sumitomo Chemical
